medigraphic.com
ISSN 2078-7170 (Electronic)

2020, Number 1

<< Back Next >>

CorSalud 2020; 12 (1)

Hydroxychloroquine and azithromycin: cardiovascular risk, QTc prolongation and sudden death in the new COVID-19 outbreak

Barja LD, Fitz MM, Chávez GE

Language: Spanish
References: 18
Page: 54-59
PDF size: 496.75 Kb.


Text Extraction

To date, huge efforts are being made to find a treatment for COVID-19. Chloroquine or hydroxychloroquine, whether or not combined with antibiotics such as azithromycin or antivirals (lopinavir/ritonavir) are among the drugs that may eventually be used.
These drugs are extensively implemented in the treatment of collagen diseases such as systemic lupus erythematosus, and other autoimmune or rheumatic diseases. They are also used in the case of parasitic (even for long-lasting treatments) and bacterial (in the case of azithromycin) infections; yet its adverse effects are by now well known. However, hydroxychloroquine, derived from chloroquine, has been largely deployed in malaria cases proving way more effective than the former.
The need for urgent action in the face of the growing pandemic coupled with the experience gained in the use of such drugs for the treatment of other viral diseases such as SARS-CoV-2 are compelling many countries such as France, China, Italy, among others to start a race of clinical trials with these drugs based on some scientific insight. At times, given the circumstances and limited time available, they are implemented early and without any kind of randomized study; something that, within the current scenario, would take up a bit of time. In fact, at this point, the appropriate doses are being considered.


REFERENCES

  1. Ministerios de Sanidad. Documento técnico: Manejo clínico del COVID-19: tratamiento médico [Internet]. Madrid: Gobierno de Espańa [citado 19 Mar 2020]; 2020. Disponible en: http://www.aeemt.com/web/wpcontent/uploads/2020/03/4_6026300193912129107.pdf

  2. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. J Am Coll Cardiol [Internet]. 2020 [citado 19 Mar 2020]: En Prensa. Disponible en: https://doi.org/10.1016/j.jacc.2020.03.031

  3. Morgan ND, Patel SV, Dvorkina O. Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus. J Clin Rheumatol. 2013;19(5):286-8.

  4. Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila). 2006;44(2):173-5.

  5. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19. Mayo Clin Proc [Internet]. 2020 [citado 20 Mar 2020];95: En Prensa. Disponible en: https://mayoclinicproceedings.org/pb/assets/raw /Health%20Advance/journals/jmcp/jmcp_covid1 9.pdf

  6. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID19. J Crit Care [Internet]. 2020 [citado 19 Mar 2020]: En Prensa. Disponible en: https://doi.org/10.1016/j.jcrc.2020.03.005

  7. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003;3(11):722-7.

  8. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M,et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents [Internet]. 2020 [citado 20 Mar 2020]: En Prensa. Disponible en: https://doi.org/10.1016/j.ijantimicag.2020.105949

  9. CredibleMeds.COVID-19 experimental therapies and TdP Risk [Internet]. En Línea 20 Marzo 2020 [citado 20 Mar 20]. Disponible en: https://crediblemeds.org/blog/covid-19- experimental-therapies-and-tdp-risk/

  10. Choi Y, Lim HS, Chung D, Choi JG, Yoon D. Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice. Biomed Res Int [Internet]. 2018 [citado 20 Mar 2020];2018:1574806. En Prensa. Disponible en: https://doi.org/10.1155/2018/1574806

  11. Guo D, Cai Y, Chai D, Liang B, Bai N, Wang R. The cardiotoxicity of macrolides: a systematic review. Pharmazie. 2010;65(9):631-40.

  12. Howard PA. Azithromycin-induced proarrhythmia and cardiovascular death. Ann Pharmacother. 2013;47(11):1547-51.

  13. Galán Martínez L, Calderín Pulido AD, FleitesVázquez A. Acción inotrópico negativa y prolongación del intervalo QT por azitromicina. Rev Cuban Cardiol [Internet]. 2017 [citado 20 Mar 2020];23(4). Disponible en: http://www.revcardiologia.sld.cu/index.php/revc ardiologia/article/view/720/pdf_108

  14. Yang Z, Prinsen JK, Bersell KR, Shen W, Yermalitskaya L, Sidorova T, et al. Azithromycin causes a novel proarrhythmic syndrome. Circ Arrhythm Electrophysiol [Internet]. 2017 [citado 20 Mar 2020];10(4):e003560. Disponible en: https://doi.org/10.1161/CIRCEP.115.003560

  15. Zhang M, Xie M, Li S, Gao Y, Xue S, Huang H, et al. Electrophysiologic studies on the risks and potential mechanism underlying the proarrhythmic nature of azithromycin. Cardiovasc Toxicol. 2017;17(4):434-40.

  16. Miranda-Aquino T, Pérez-Topete SE, Ortega-Pantoja W, Gómez-Vázquez CA, Meneses-Pérez LG, González-Padilla C, et al. Síndrome de QT largo secundario a la interacción entre hidroxicloroquina y amiodarona. Rev Mex Cardiol. 2018;29(2): 98-101.

  17. Taira CA, Opezzo JA, Mayer MA, Höcht C. Cardiovascular drugs inducing QT prolongation: facts and evidence. Curr Drug Saf. 2010;5(1):65-72.

  18. CredibleMeds. Risk Categories for Drugs that Prolong QT & induce Torsades de Pointes (TdP) [Internet]. Última revisión 19 Marzo 2020 [citado 20 Mar 2020]. Disponible en: https://crediblemeds.org/new-drug-list/




2020     |     www.medigraphic.com